Northwood, OH – April 2016 – NAMSA, the world’s leading medical research organization, is pleased to announce the addition of Hasten LLC as NAMSA’s local agent in Brazil and Mexico.
Hasten is a USA International Sales Broker and consulting network supporting Latin American and multinational device manufacturers in the region.
Together, Hasten LLC and NAMSA offerings include: preclinical testing, global regulatory strategy and submissions, National Health Surveillance Agency (ANVISA) regulatory support, global clinical research, quality systems, compliance support, and government affairs.
“NAMSA’s get-to-market, development knowledge in the major device markets combined with Hasten’s relationships in Latin America will provide the right support for local manufacturers and innovators who seek foreign market approval and adoption,” said Eduardo De Melo, President of Hasten LLC. “We are also collaborating with NAMSA in further development of optimal Brazilian and Mexican registration support for US, EU, and Chinese manufacturers entering the region.”
“The addition of Hasten LLC as a representing agent demonstrates NAMSA’s commitment to global growth of service offerings and support for our clients around the world,” stated John Amat, NAMSA’s Chief Commercial Officer. “Their expertise in Brazil and Mexico will provide added value to our client’s reach for their global device commercialization needs.”
About Hasten LLC
Hasten LLC (www.hasten-llc.com) specializes in the Health industry with a keen eye on business opportunities in emerging countries. One of their main differentials is their capacity to combine the knowledge of the culture and demands of the international investor to the way business is done in Brazil and Latin America in human and animal health segments.
NAMSA (www.namsa.com) is a Medical Research Organization (MRO), accelerating medical device product development through integrated laboratory, clinical and consulting services. Driven by our regulatory expertise, NAMSA’s MRO® Approach plays an important role in translational research, applying a unique combination of disciplines—consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality—to move client’s products through the development process, and continue to provide support through commercialization to post-market requirements, anywhere in the world.
For further information about NAMSA or this news release, contact:
Chief Commercial Officer
6750 Wales Rd Northwood, OH 43619